title: Corneal gene therapy: basic science and translational perspective.
abstract: Corneal blindness is the third leading cause of blindness worldwide. Gene therapy is an emerging technology for corneal blindness due to the accessibility and immune-privileged nature of the cornea, ease of vector administration and visual monitoring, and ability to perform frequent noninvasive corneal assessment. Vision restoration by gene therapy is contingent upon vector and mode of therapeutic gene introduction into targeted cells/tissues. Numerous efficacious vectors, delivery techniques, and approaches have evolved in the last decade for developing gene-based interventions for corneal diseases. Maximizing the potential benefits of gene therapy requires efficient and sustained therapeutic gene expression in target cells, low toxicity, and a high safety profile. This review describes the basic science associated with many gene therapy vectors and the present progress of gene therapy carried out for various ocular surface disorders and diseases.
authors.affiliation: Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri, USA. mohanr@health.missouri.edu
authors.forename: Rajiv R
authors.initials: RR
authors.lastname: Mohan
authors.forename: Jason T
authors.initials: JT
authors.lastname: Rodier
authors.forename: Ajay
authors.initials: A
authors.lastname: Sharma
mesh_terms: D035843:Biomedical Research; D003316:Corneal Diseases / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans
keywords: adeno-associated virus; adenovirus; cornea; corneal diseases and dystrophies; gene therapy; lentivirus; nanoparticles; retrovirus